NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 228
(Total Views: 139)
Posted On: 11/02/2023 4:36:37 PM
NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled for Nov. 5–7, 2023, in Miami. According to the announcement, the oral presentation is based on an abstract describing the phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with rare genetic skin disease called epidermolysis bullosa (“EB”). InMed Pharmaceuticals senior vice president of Clinical and Regulatory Affairs Alexandra Mancini will be presenting. The abstract title is “INM-755 Cannabinol Cream Demonstrates Anti-Itch Activity in Patients with Epidermolysis Bullosa.” Mancini’s presentation is scheduled to begin at 4:08 p.m. ET on Nov. 7. Designed to evaluate the safety of INM-755 CBN cream, the phase 2 within-patient, double-blind study gathered preliminary evidence of the cream’s efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. The data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone. A copy of the poster and other presentation materials will be on the company’s website following the event.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled for Nov. 5–7, 2023, in Miami. According to the announcement, the oral presentation is based on an abstract describing the phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with rare genetic skin disease called epidermolysis bullosa (“EB”). InMed Pharmaceuticals senior vice president of Clinical and Regulatory Affairs Alexandra Mancini will be presenting. The abstract title is “INM-755 Cannabinol Cream Demonstrates Anti-Itch Activity in Patients with Epidermolysis Bullosa.” Mancini’s presentation is scheduled to begin at 4:08 p.m. ET on Nov. 7. Designed to evaluate the safety of INM-755 CBN cream, the phase 2 within-patient, double-blind study gathered preliminary evidence of the cream’s efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. The data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone. A copy of the poster and other presentation materials will be on the company’s website following the event.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)InMed Pharmaceuticals, Inc. (INM) Stock Research Links
Scroll down for more posts ▼